CN106362168A - Experimental method for medicament capable of treating hyperuresis caused by lithium salt - Google Patents
Experimental method for medicament capable of treating hyperuresis caused by lithium salt Download PDFInfo
- Publication number
- CN106362168A CN106362168A CN201611003924.2A CN201611003924A CN106362168A CN 106362168 A CN106362168 A CN 106362168A CN 201611003924 A CN201611003924 A CN 201611003924A CN 106362168 A CN106362168 A CN 106362168A
- Authority
- CN
- China
- Prior art keywords
- rotenone
- dosage
- polyuria
- experimental method
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Abstract
The invention discloses an experimental method for a medicament capable of treating hyperuresis caused by lithium salt. Compared with the prior art, the experimental method is characterized in that by virtue of intervention of low-dosage rotenone (in general research, the rotenone dosage is 500-600ppm, and the rotenone dosage in research of the invention is 200ppm), diuresis is improved by at least 80%. Rotenone is a mitochondrion activity inhibitor. The research result indicates that through properly inhibiting the mitochondrion activity of a kidney, diabetes relevant to lithium salts can be effectively improved, the rotenone has certain clinical application prospect, is beneficial to medical effect research and preparation of medicines and has popularization and application value.
Description
Technical field
The present invention relates to a kind of medicine makes experimental technique, more particularly, to a kind of treat the polyuria disease drug that lithium salts causes
Experimental technique.
Background technology
Lithium salts is the most effective medicine of current clinical treatment depression, is particularly reducing Suicide of Depression Patients tendency
Upper effect is difficult to substitute.But about half above patient has serious renal tubular function after long-term taking lithium salts preparation and damages
, kidney concentrating function obstacle (polyuria, some patients' urine volume up to normal person's several times more than), seriously limits this medicine in wound
The clinical practice of thing.Clinically do not treat the effective way of the polyuria that lithium salts leads at present.And in some patients
This effect is irreversible, even if disabling lithium salts preparation, polyuria still cannot be alleviated, and is a puzzlement doctor and patient
Important clinical problem.Therefore, seek the Therapeutic Method not only clinical urgency of the polyuria that effectively treatment lithium salts causes,
Also have huge market development demand.
Content of the invention
The purpose of the present invention is that to provide to solve the above problems a kind of treats the polyuria disease drug that lithium salts causes
Experimental technique.
The present invention is achieved through the following technical solutions above-mentioned purpose:
The present invention comprises the following steps:
(1) the polyuria model of lumbar injection lithium chloride induction once a day, dosage is 4mmol/ days；
(2) while giving lithium chloride process, in food, give rotenone 200ppm；
(3) collect urine volume at the 9th day, weigh the weight of animals, analysis urine volume change；
(4), after collecting urine sample, mice, the expression of analysis renal tissue aquaporin 2 (aqp2) are put to death.
The beneficial effects of the present invention is:
The present invention is a kind of experimental technique treating the polyuria disease drug that lithium salts causes, compared with prior art, the present invention
By low dosage rotenone, (in general Study, the dosage of rotenone is 500-600ppm, and the dosage that this research uses is
200ppm) intervene, polyuria is enhanced more than 80%.Rotenone is a kind of mitochondria activity inhibitor, and this result of study is pointed out, and leads to
Cross the mitochondria activity suitably suppressing kidney, the related polyuria of lithium salts can be effectively improved, before there is certain clinical practice
Scape, the drug efficacy study beneficial to medicine makes, and has the value of popularization and application.
Specific embodiment
The invention will be further described below:
The present invention comprises the following steps:
(1) the polyuria model of lumbar injection lithium chloride induction once a day, dosage is 4mmol/ days；
(2) while giving lithium chloride process, in food, give rotenone 200ppm；
(3) collect urine volume at the 9th day, weigh the weight of animals, analysis urine volume change；
(4), after collecting urine sample, mice, the expression of analysis renal tissue aquaporin 2 (aqp2) are put to death.
Present invention application lithium chloride gives lumbar injection (4mmol/kg/day), successfully induces polyuria model, in chlorine
Change lithium to process the 9th day, and matched group compares (normal group urine volume 2.5ml/24h), urine volume reaches 8.2ml/24h.Giving low dose
After amount rotenone (200ppm) suppression Mitochondria complex 1 activity, lithium chloride polyuria together is lowered to 3.5ml/24h, suppression
Effect processed reaches more than 80%.Urine infiltration has also obtained corresponding improvement in the reduction of lithium chloride group.In body weight, and lithium chloride
Group compares (average 22.7g), rotenone group Non Apparent Abnormality (average weight 22.5g), and general state is also without exception.Divide further
The expression of analysis kidney aqp2, the reduction of the aqp2 that lithium chloride causes has obtained very significantly improving.
Ultimate principle and principal character and the advantages of the present invention of the present invention have been shown and described above.The technology of the industry
, it should be appreciated that the present invention is not restricted to the described embodiments, the simply explanation described in above-described embodiment and description is originally for personnel
The principle of invention, without departing from the spirit and scope of the present invention, the present invention also has various changes and modifications, these changes
Change and improvement both falls within scope of the claimed invention.Claimed scope by appending claims and its
Equivalent thereof.
Claims (1)
1. a kind of experimental technique treating the polyuria disease drug that lithium salts causes it is characterised in that: comprise the following steps:
(1) the polyuria model of lumbar injection lithium chloride induction once a day, dosage is 4mmol/ days；
(2) while giving lithium chloride process, in food, give rotenone 200ppm；
(3) collect urine volume at the 9th day, weigh the weight of animals, analysis urine volume change；
(4), after collecting urine sample, mice, the expression of analysis renal tissue aquaporin 2 (aqp2) are put to death.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611003924.2A CN106362168A (en) | 2016-11-15 | 2016-11-15 | Experimental method for medicament capable of treating hyperuresis caused by lithium salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611003924.2A CN106362168A (en) | 2016-11-15 | 2016-11-15 | Experimental method for medicament capable of treating hyperuresis caused by lithium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106362168A true CN106362168A (en) | 2017-02-01 |
Family
ID=57893862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611003924.2A Pending CN106362168A (en) | 2016-11-15 | 2016-11-15 | Experimental method for medicament capable of treating hyperuresis caused by lithium salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106362168A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524492A (en) * | 2018-06-22 | 2018-09-14 | 南京市儿童医院 | Application of the rotenone in preparing medicine for treating diabetic nephropathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997768A (en) * | 2015-07-23 | 2015-10-28 | 上海市第六人民医院 | Application of rotenone in preparing blood glucose reduction medicine |
-
2016
- 2016-11-15 CN CN201611003924.2A patent/CN106362168A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997768A (en) * | 2015-07-23 | 2015-10-28 | 上海市第六人民医院 | Application of rotenone in preparing blood glucose reduction medicine |
Non-Patent Citations (2)
| Title |
|---|
| XU CHENG ET AL.: "CYCLOOXYGENASE-2 INHIBITOR PRESERVES MEDULLARY AQUAPORIN-2 EXPRESSION AND PREVENTS POLYURIA AFTER URETERAL OBSTRUCTION", 《THE JOURNAL OF UROLOGY》 * |
| YING SUN ET AL.: "Inhibition of mitochondrial complex-1 restores the downregulation of aquaporins in obstructive nephropathy", 《AM J PHYSIOL RENAL PHYSIOL 》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524492A (en) * | 2018-06-22 | 2018-09-14 | 南京市儿童医院 | Application of the rotenone in preparing medicine for treating diabetic nephropathy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102791277B (en) | The improvement of chronic prostatitis, interstitial cystitis and/or urination disorder or therapeutic agent | |
| CN106362168A (en) | Experimental method for medicament capable of treating hyperuresis caused by lithium salt | |
| CN1927286A (en) | Chinese medicine composition for treating skin disease | |
| SHAFAT et al. | Reversal of cardiovascular toxicity in severe organophosphate poisoning with 20% Intralipid emulsion therapy: case report and review of literature | |
| CN102048850B (en) | Traditional Chinese medicine external preparation for curing infantile eczema and preparing method thereof | |
| CN103989695A (en) | Pharmaceutical composition for treating bronchial asthma and application thereof | |
| CN107375311B (en) | Pharmaceutical use of liquiritin for treating neuropathic pain | |
| CN101274064A (en) | Chinese medicinal preparation for hydrophobic | |
| CN102406788A (en) | Traditional Chinese preparation for treating vitiligo | |
| CN103599438B (en) | A kind of Traditional Chinese medicine tincture for the treatment of osteopathia and preparation method thereof | |
| Lloyd et al. | Choreoathetosis in the setting of lithium toxicity | |
| CN107335011A (en) | Treat the external application Chinese medicine compound preparation of cancer pain | |
| CN102274330B (en) | Medicament for treating beriberi | |
| CN107812006A (en) | One kind treats acute renal failure pharmaceutical composition and its application | |
| CN101134098A (en) | Traditional Chinese medicine for treating biliary ascariasis | |
| CN106309457B (en) | A kind of ursolic acid-Aspirin Conjugate is preparing the application in liver protecting drug | |
| CN101244150B (en) | Medicament for treating enteritis | |
| CN109745342A (en) | It is a kind of for treat the Chinese medicine composition of idiopathic epilepsy with and preparation method thereof and application method | |
| CN117338774A (en) | Antidepressant activity of inhibitor TMP269 | |
| CN104083673A (en) | Traditional Chinese medicine composition for treating chronic glomerulonephritis and application of traditional Chinese medicine composition | |
| CN105770339A (en) | Medicament for treating acnes | |
| CN109620833A (en) | Application of the acetyl elemolic acid in preparation prevention and treatment Acute or chronic pain drug | |
| SHEBEKO | THE STUDY OF DOSE DEPENDENCE OF HYPOAZOTEMIC EFFECT OF THE COMBINATION OF QUERCETIN WITH GLUCOSAMINE DERIVATIVES IN CONDITIONS OF RENAL FAILURE IN RATS | |
| CN109568306A (en) | 2 methyl -5- acetyl -4- furans Ji Ma -1(10)-alkene -6- ketone preparing the application in analgesic | |
| CN104415171A (en) | Bone-strengthening injection liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |